(Q43923299)

28 November 2017

title

Effects and serum levels of glibenclamide and its active metabolites in patients with type 2 diabetes (English)

1 reference

28 November 2017

1 reference

Jönsson A

1

1 reference

28 November 2017

Hallengren B

series ordinal

2

1 reference

28 November 2017

Rydberg T

series ordinal

3

1 reference

28 November 2017

Melander A

series ordinal

4

1 reference

28 November 2017

publication date

1 December 2001

1 reference

Diabetes, Obesity and Metabolism

28 November 2017

published in

1 reference

28 November 2017

volume

3

1 reference

28 November 2017

issue

6

1 reference

28 November 2017

page(s)

403-409

1 reference

Sulphonylurea therapy doubles B-cell response to glucose in type 2 diabetic patients.

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00152.X

The long-term effects of chlorpropamide on insulin, C-peptide, and proinsulin secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00152.X

Effect of sulphonylurea therapy on plasma insulin, intact and 32/33 split proinsulin in subjects with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00152.X

Elevated ratio of summed serum proinsulin to insulin response after oral glucose load in type 2 diabetes decreases following sulfonylurea treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00152.X

Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00152.X

Impaired effect of sulfonylurea following increased dosage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00152.X

Serum glibenclamide in diabetic patients, and influence of food on the kinetics and effects of glibenclamide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00152.X

Sensitive and specific two-site immunoradiometric assays for human insulin, proinsulin, 65-66 split and 32-33 split proinsulins

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00152.X

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00152.X

Acarbose controls postprandial hyperproinsulinemia in non-insulin dependent diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00152.X

Effect of insulin versus sulfonylurea therapy on cardiovascular risk factors and fibrinolysis in type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00152.X

Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00152.X

Pharmacodynamics and pharmacokinetics of intravenous glibenclamide in Caucasian and Chinese patients with type-2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00152.X

Effects and pharmacokinetics of oral glibenclamide and glipizide in Caucasian and Chinese patients with type-2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1463-1326.2001.00152.X

10.1046/J.1463-1326.2001.00152.X

21 January 2018

Identifiers

DOI

1 reference

28 November 2017

1 reference